Skip to main content
. Author manuscript; available in PMC: 2020 Oct 30.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2019 Dec 21;47(6):1446–1457. doi: 10.1007/s00259-019-04628-6

Figure 3.

Figure 3.

(A) 18F-Fluorocholine PET SUVmax as a function of follow-up time for n=13 pts (follow-up was not established for one international patient). Blue circles - deceased from previously treated progressing brain metastases (n=5). Orange square - deceased from progressing metastases in the liver and pancreas (n=1) and previously untreated brain metastases (n=1). Red diamonds - alive (n=6). Dashed line represents 18F-Fluorocholine PET SUVmax = 6 (median value), splitting the data into two groups. (B) Kaplan-Meier estimator for groups 1 and 2. Observations were censored if the patient was alive at the time of last follow-up or deceased from cause other than progression in the treated brain metastases. Difference in survival distributions did not reach significance according to the log-rank test (p=0.068).